Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of “Moderate Buy” by Analysts

Posted by Geri Gentry on Jul 11th, 2026

Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) has earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $6.1667.

CNTX has been the topic of a number of recent analyst reports. Wall Street Zen lowered Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Maxim Group decreased their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Piper Sandler increased their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th.

Read Our Latest Stock Analysis on Context Therapeutics

Context Therapeutics Trading Up 9.8%

Shares of NASDAQ CNTX opened at $0.65 on Monday. Context Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.62. The stock’s 50 day simple moving average is $1.60 and its 200 day simple moving average is $2.02. The company has a market cap of $59.99 million, a price-to-earnings ratio of -1.55 and a beta of 1.75.

Context Therapeutics (NASDAQ:CNTX – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. As a group, equities analysts forecast that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after buying an additional 134,449 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 3rd quarter worth approximately $100,000. Blue Owl Capital Holdings LP increased its position in shares of Context Therapeutics by 0.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares during the period. Renaissance Technologies LLC lifted its position in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares during the period. Finally, State Street Corp lifted its position in Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares during the period. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

(Get Free Report)

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.